Dalzanemdor (; development code SAGE-718) is experimental drug being investigated for the treatment of neurological disorders and cognitive impairment. It acts as a positive allosteric modulator of the NMDA receptor, whose activity is essential for learning, memory, and cognition. Dalzanemdor is an analogue of the neurosteroid 24S-hydroxycholesterol.
As of 2022, dalzanemdor is in Phase II clinical trials for Alzheimer's disease, Parkinson's disease, and Huntington's disease.